Loading stock data…
Upstream Bio (UPB)
$6.19+0.18 (+3.00%)
Market ClosedLast close Sep 8
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Upstream Bio, Inc. in the Healthcare sector is trading at $6.19 with a market capitalization of $324M. Wall Street consensus targets $31.14 (7 analysts), implying a +403.1% move over the next 12 months. The stock is currently near its 52-week low of $5.77, remaining 55.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +403.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.03M↑ | $668,000↓ | $683,000↓ | $937,000↑ | $566,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.62M↑ | -$46.17M↓ | -$37.83M↑ | -$44.35M↓ | -$32.01M |
| Net Income | -$40.59M↑ | -$42.46M↓ | -$33.75M↑ | -$39.97M↓ | -$27.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$324.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.57%
Volume
Today's trading volume
949,038
Recent News
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027
Upstream Bio (UPB) is on track to initiate Phase 3 clinical trials of verekitug in severe asthma and
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Upstream Bio, Inc. (NASDAQ:UPB) is one of the most promising stocks on our list. TheFly reported on June 3 that H.C. Wainwright analyst Matthew Caufield initiated coverage of UPB with a Buy rating and a $36 price target. The […]
Is Upstream Bio, Inc. (UPB) the Best Low Priced Stocks to Get Rich in 2026?
Upstream Bio, Inc. (NASDAQ:UPB) is among the best low priced stocks to get rich in 2026. On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, while downgrading the stock from Overweight to Neutral. In a research note, the analyst said that other peers in asthma are […]